Key facts
- Tavira Therapeutics’s last known valuation is $2.3M (Nov 2025).
- It has raised $1.4M; the latest was Seed Round ($1.4M) in Nov 2025.
- Notable investors include General Inception, VLAIO.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Tavira Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Tavira Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Tavira Therapeutics
Developer of an advanced AAV delivery platform designed to treat genetic disorders. The company's platform offers equips AAV vectors with molecules to accurately target the intended tissues, enabling clients to develop efficient gene therapies with reduced side effects.
- Sector
- Healthcare
- HQ
- Leuven, Belgium
- Founded
- 2023
- Employees
- 9
- Website
- taviratx.com/
- Ownership
- Privately Held (backing)
Tavira Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Tavira Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Tavira Therapeutics in its N-PORT filings yet. We sweep new filings monthly.